Every Form 4 that Inuvo, Inc. (INUV) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow INUV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INUV filings page.
Inuvo, Inc. Chief Executive Officer Robert C. Buchner exercised 41,666 restricted stock units on October 1, 2026, acquiring 41,666 shares of common stock. On the same date, 12,024 common shares were delivered or withheld for payment of exercise price or tax liability. His reported post-transaction balance was 83,334 restricted stock units. Each unit represents a contingent right to one common share, and the units vest 33.33% per year beginning on the first anniversary of the grant date.
Inuvo, Inc. (symbol: INUV) is the issuer of record for a Form 4/A filing submitted to the SEC.
Inuvo, Inc. (symbol: INUV) is the issuer of record for a Form 4/A filing submitted to the SEC.
Inuvo, Inc. (INUV) reports an amended insider transaction for a director. The reporting person, a director of Inuvo, received a grant of 30,702 Restricted Stock Units on July 1, 2026, recorded as a derivative security with no cash exercise price.
Each restricted stock unit represents a contingent right to receive one share of Inuvo common stock, for a total of 30,702 underlying shares, with both the exercise and expiration date shown as January 1, 2027. The amendment corrects the exercisable date disclosure from July 1, 2027 to January 1, 2027.
Inuvo, Inc. (symbol: INUV) is the issuer of record for a Form 4/A filing submitted to the SEC.
Inuvo, Inc. (symbol: INUV) is the issuer of record for a Form 4 filing submitted to the SEC.
Partalo Sanja reported acquisition or exercise transactions in this Form 4 filing.
Inuvo, Inc. director Sanja Partalo reported receiving a grant of restricted stock units. On July 1, 2026, Partalo was awarded 30,702 restricted stock units, each representing a contingent right to receive one share of Inuvo common stock. The award was reported at a price of $0.00 per unit, reflecting that it is a compensation grant rather than a market purchase. Following this grant, Partalo holds 30,702 restricted stock units directly, all tied to Inuvo common shares.
Inuvo, Inc. director Richard K. Howe reported routine equity compensation activity involving common stock and restricted stock units. On July 1, 2026, he exercised 7,500 restricted stock units into the same number of common shares and had 3,112 shares withheld at $1.14 per share to cover tax obligations, which is not an open-market sale.
He also received a new grant of 30,702 restricted stock units, each representing a contingent right to one share of common stock. Following these transactions, Howe directly held 555,416 common shares and 30,702 restricted stock units. The filing reflects compensation and tax mechanics rather than discretionary buying or selling.
Cameron Gordon J reported acquisition or exercise transactions in this Form 4 filing.
Inuvo, Inc. director Cameron J. Gordon received a grant of 30,702 restricted stock units. The award was made as a compensation grant on July 1, 2026 and carries a price of $0.00 per unit. Each restricted stock unit represents a contingent right to receive one share of Inuvo’s common stock. Following this grant, Gordon holds 30,702 restricted stock units directly.
Bond Jonathan reported acquisition or exercise transactions in this Form 4 filing.
Inuvo, Inc. director Jonathan Bond reported receiving a grant of 30,702 restricted stock units. Each unit represents a contingent right to receive one share of Inuvo common stock, so the award covers 30,702 underlying shares. Following this compensation grant, his reported derivative holdings total 30,702 units.
Inuvo, Inc.'s CFO Wallace D. Ruiz exercised restricted stock units into common shares and had part of the award withheld for taxes. On the transaction date, 7,500 restricted stock units converted into 7,500 shares of common stock. Of these, 3,739 shares were withheld at a price of $2.14 per share to satisfy tax obligations. After these compensation-related transactions, Ruiz directly held 126,367 shares of Inuvo common stock. The affected restricted stock units vest in three equal annual installments, and the figures are adjusted for a previously completed 1-for-10 reverse stock split.
Inuvo, Inc. director Richard K. Howe exercised equity awards and settled related taxes. On April 1, 2026, he exercised 36,667 restricted stock units, receiving the same number of common shares at a reported exercise price of $0.00 per share.
To cover tax obligations, 15,143 common shares were withheld at $2.14 per share as a tax-withholding disposition. After these transactions, Howe directly held 547,916 shares of Inuvo common stock. All referenced restricted stock units represent a contingent right to receive one share of common stock each and were adjusted for a prior 1-for-10 reverse stock split.
Inuvo CFO Wallace D Ruiz exercised 10,000 restricted stock units on March 1, 2026, receiving an equal number of common shares at $0 per share. To satisfy tax obligations, 5,034 common shares were withheld at $2.55 per share. After these transactions, he directly holds 122,606 shares of Inuvo common stock. Each restricted stock unit represents one share, and the reported amounts reflect a prior 1-for-10 reverse stock split.
Inuvo, Inc. director Richard K. Howe reported equity compensation-related transactions. On March 1, 2026, he exercised 41,667 restricted stock units, converting them into 41,667 shares of common stock at a price of $0.00 per share. Each restricted stock unit represented a contingent right to receive one share of common stock.
On the same date, Howe disposed of 19,411 common shares at $2.55 per share in a tax-withholding transaction used to satisfy tax liabilities arising from the equity award. After these transactions, he held 526,392 shares of Inuvo common stock directly.
Inuvo, Inc. reported that Chief Executive Officer and director Robert C. Buchner received a grant of 75,000 restricted stock units on February 1, 2026. Each unit represents the right to receive one share of Inuvo common stock at no cash exercise price.
The restricted stock units vest in installments of 33.33% per year, beginning on the first anniversary of the grant date and continuing annually until fully vested by February 1, 2029. Following this grant, Buchner directly beneficially owns 75,000 derivative securities tied to Inuvo common stock.
Inuvo, Inc. director Kenneth Ewell Lee reported the conversion of restricted stock units into common shares. On 01/08/2026, 3,000 restricted stock units were converted into 3,000 shares of Inuvo common stock at a price of $0.0000 per share through a transaction coded "M". After this transaction, Lee directly beneficially owned 54,500 shares of Inuvo common stock.
The filing notes that the share amounts were adjusted to reflect a 1-for-10 reverse stock split that occurred on June 10, 2025, and that each restricted stock unit represents a contingent right to receive one share of Inuvo common stock.
Inuvo, Inc. director Gordon J. Cameron reported a stock-based compensation transaction. On January 8, 2026, 3,000 restricted stock units were converted into 3,000 shares of Inuvo common stock at an exercise price of $0.0000, reflecting the vesting and settlement of equity awards rather than an open-market purchase. Following this transaction, Cameron beneficially owns 57,910 shares of Inuvo common stock directly and an additional 663 shares indirectly through his spouse. The reported share amounts have been adjusted to reflect a 1-for-10 reverse stock split that occurred on June 10, 2025.
Inuvo, Inc. reported that Chief Operating Officer and director Robert C. Buchner acquired common stock through the settlement of equity awards. On January 8, 2026, 3,000 restricted stock units were converted into 3,000 shares of common stock at an exercise price of $0.0000 per share. Following this transaction, Buchner directly holds 3,000 shares of Inuvo common stock. The number of restricted stock units and underlying shares reflects a 1-for-10 reverse stock split that occurred on June 10, 2025.
Inuvo, Inc. director Jonathan Bond reported the conversion of 3,000 restricted stock units into 3,000 shares of common stock on January 8, 2026. The Form 4 shows this as a code "M" transaction at a price of $0.0000 per share, indicating an exercise of equity awards rather than an open-market purchase.
After this transaction, Bond directly owns 12,000 shares of Inuvo common stock. The filing notes that the figures have been adjusted for a 1-for-10 reverse stock split that occurred on June 10, 2025. The derivative position in these restricted stock units is now reported as 0, reflecting that all 3,000 units referenced here have been converted into common shares.
Inuvo, Inc. director Kenneth Ewell Lee reported a new equity award. On 01/02/2026, he received 3,000 restricted stock units, each representing a contingent right to receive one share of Inuvo common stock. The units are listed as a derivative security with a conversion price of $0.0000 and are exercisable beginning 01/04/2027, with an expiration date of 01/04/2027. Following this transaction, he beneficially owns 3,000 derivative securities directly.
Inuvo, Inc. reported that one of its directors acquired equity-based compensation in the form of derivative securities. On 01/02/2026, the director received 3,000 restricted stock units, each representing a contingent right to receive one share of Inuvo common stock. The restricted stock units were acquired at a price of $0.0000 per unit and are listed as directly owned derivative securities. Following this grant, the director beneficially owns 3,000 derivative securities tied to Inuvo common stock, with the units shown as exercisable and expiring on 01/04/2027.
Inuvo, Inc. director Jonathan Bond reported receiving a grant of 3,000 restricted stock units of the company’s common stock. The Form 4 shows the RSU transaction date as 01/02/2026, with the units listed as directly owned. Each restricted stock unit represents a contingent right to receive one share of Inuvo common stock, and the RSUs have a date exercisable and expiration date of 01/04/2027. The transaction is reported as an acquisition of derivative securities at a stated price of $0.0000 per RSU.
Inuvo, Inc. disclosed an insider equity transaction involving its Chief Financial Officer, Wallace D. Ruiz. On December 11, 2025, 14,100 restricted stock units converted into an equal number of common shares of Inuvo common stock at an exercise price of $0.0000 per share.
On the same date, 6,999 common shares were disposed of at $3.01 per share. Following these transactions, Ruiz directly beneficially owned 117,640 shares of Inuvo common stock. The RSU amount was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 10, 2025.
Inuvo, Inc. Chairman and CEO Richard K. Howe, who also serves as a director, reported stock transactions dated 12/11/2025. He acquired 46,002 shares of common stock at $0.0000 upon settlement of restricted stock units and disposed of 25,873 shares at $3.01 per share. After these transactions, he beneficially owned 504,136 shares of Inuvo common stock directly. The filing states that each restricted stock unit represented a right to receive one share of common stock and that the share amounts were adjusted for a 1-for-10 reverse stock split that occurred on June 10, 2025.